المؤلفون: Zeng H; GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Department of Radiation Oncology (Maastro), Maastricht, the Netherlands. Electronic address: janezenghaiyan@outlook.com., Hendriks LEL; GROW - School for Oncology and Reproduction, Maastricht University Medical Center+, Department of Pulmonary Diseases, Maastricht, the Netherlands. Electronic address: lizza.hendriks@mumc.nl., Witlox WJA; GROW - School for Oncology and Reproduction, CAPHRI- School for Public Health and Primary Care, Maastricht University Medical Center+, Maastricht, the Netherlands. Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, the Netherlands. Electronic address: willem.witlox@mumc.nl., Groen HJM; University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, the Netherlands. Electronic address: h.j.m.groen@umcg.nl., Dingemans AC; Erasmus MC Cancer Institute, University Medical Center, Department of Pulmonary Diseases, Rotterdam, the Netherlands. Electronic address: a.dingemans@erasmusmc.nl., Praag J; Erasmus MC Cancer Institute, Department of Radiation Oncology, Rotterdam, the Netherlands. Electronic address: j.praag@erasmusmc.nl., Belderbos J; The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Department of Radiation Oncology, Amsterdam, the Netherlands. Electronic address: j.belderbos@nki.nl., Houben R; GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Department of Radiation Oncology (Maastro), Maastricht, the Netherlands. Electronic address: ruud.houben@maastro.nl., van der Noort V; The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Department of biometrics, Amsterdam, the Netherlands. Electronic address: v.vd.noort@nki.nl., De Ruysscher DKM; GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Department of Radiation Oncology (Maastro), Maastricht, the Netherlands. Electronic address: dirk.deruysscher@maastro.nl.

المصدر: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2023 Jun; Vol. 183, pp. 109627. Date of Electronic Publication: 2023 Mar 18.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8407192 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0887 (Electronic) Linking ISSN: 01678140 NLM ISO Abbreviation: Radiother Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Brain Neoplasms*/prevention & control , Carcinoma, Non-Small-Cell Lung*/radiotherapy , Carcinoma, Non-Small-Cell Lung*/pathology , Cognitive Dysfunction*/etiology , Lung Neoplasms*/radiotherapy , Lung Neoplasms*/pathology, Humans ; Neoplasm Recurrence, Local ; Risk Factors

المؤلفون: Baker S; Department of Radiation Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 302, Postbus 2040, 3000 CA, Rotterdam, The Netherlands. baker2@ualberta.ca., Bakunina K; Department of Radiation Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 302, Postbus 2040, 3000 CA, Rotterdam, The Netherlands., Duijm M; Department of Radiation Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 302, Postbus 2040, 3000 CA, Rotterdam, The Netherlands., Hoogeman MS; Department of Radiation Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 302, Postbus 2040, 3000 CA, Rotterdam, The Netherlands., Cornelissen R; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, s Gravendijkwal 230, 3015 CD, Rotterdam, The Netherlands., Antonisse I; Department of Radiation Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 302, Postbus 2040, 3000 CA, Rotterdam, The Netherlands., Praag J; Department of Radiation Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 302, Postbus 2040, 3000 CA, Rotterdam, The Netherlands., Heemsbergen WD; Department of Radiation Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 302, Postbus 2040, 3000 CA, Rotterdam, The Netherlands., Nuyttens JJ; Department of Radiation Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 302, Postbus 2040, 3000 CA, Rotterdam, The Netherlands.

المصدر: Radiation oncology (London, England) [Radiat Oncol] 2020 Apr 22; Vol. 15 (1), pp. 89. Date of Electronic Publication: 2020 Apr 22.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101265111 Publication Model: Electronic Cited Medium: Internet ISSN: 1748-717X (Electronic) Linking ISSN: 1748717X NLM ISO Abbreviation: Radiat Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Nomograms*, Carcinoma, Non-Small-Cell Lung/*radiotherapy , Lung Neoplasms/*radiotherapy , Radiosurgery/*mortality, Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prognosis ; Proportional Hazards Models ; Reproducibility of Results

المؤلفون: Witlox WJA; Maastricht University Medical Centre(+), Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, The Netherlands. Electronic address: willem.witlox@mumc.nl., Ramaekers BLT; Maastricht University Medical Centre(+), Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, The Netherlands., Joore MA; Maastricht University Medical Centre(+), Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, The Netherlands; Care and Public Health Research Institute (CAPHRI), Maastricht University, The Netherlands., Dingemans AC; Maastricht University Medical Center(+), Department of Pulmonology, GROW Research Institute, The Netherlands., Praag J; Erasmus University Medical Center, Department of Radiation Oncology, Rotterdam, The Netherlands., Belderbos J; Netherlands Cancer Institute (NKI), Department of Radiation Oncology, Amsterdam, The Netherlands., Tissing-Tan C; Radiotherapy Institute Arnhem, Arnhem, The Netherlands., Herder G; Antonius Hospital Nieuwegein, Department of Pulmonology, The Netherlands., Haitjema T; Medical Center Alkmaar, Department of Pulmonology, The Netherlands., Ubbels JF; University of Groningen, University Medical Center Groningen, Department of Radiation Oncology, The Netherlands., Lagerwaard J; Free University Medical Center, Department of Radiation Oncology, Amsterdam, The Netherlands., El Sharouni SY; University Medical Center Utrecht, Department of Radiation Oncology, The Netherlands., Stigt JA; Isala Hospital, Department of Pulmonology, Zwolle, The Netherlands., Smit EF; Netherlands Cancer Institute (NKI), Department of Pulmonology, Amsterdam, The Netherlands., van Tinteren H; Netherlands Cancer Institute (NKI), Department of Biometrics, Amsterdam, The Netherlands., van der Noort V; Netherlands Cancer Institute (NKI), Department of Biometrics, Amsterdam, The Netherlands., Groen HJM; University of Groningen and University Medical Center Groningen, Department of Pulmonary Diseases, The Netherlands., De Ruysscher DKM; Maastricht University Medical Centre(+), Department of Radiation Oncology (Maastro Clinic), GROW School of Oncology and Developmental Biology, The Netherlands; KU Leuven, Radiation Oncology, Belgium.

المصدر: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2020 Mar; Vol. 144, pp. 65-71. Date of Electronic Publication: 2019 Nov 14.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8407192 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0887 (Electronic) Linking ISSN: 01678140 NLM ISO Abbreviation: Radiother Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/radiotherapy , Lung Neoplasms*/radiotherapy, Cranial Irradiation ; Health Status ; Humans ; Quality of Life ; Surveys and Questionnaires

المؤلفون: Witlox WJA; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre (MUMC) , Maastricht , The Netherlands., Ramaekers BLT; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre (MUMC) , Maastricht , The Netherlands., Groen HJM; Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen , Groningen , The Netherlands., Dingemans AM; Department of Pulmonology, Maastricht University Medical Center, GROW Research Institute , Maastricht , The Netherlands., Praag J; Department of Radiation Oncology, Erasmus University Medical Center , Rotterdam , The Netherlands., Belderbos J; Department of Radiation Oncology, Netherlands Cancer Institute (NKI) , Amsterdam , The Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute (NKI) , Amsterdam , The Netherlands., van Tinteren H; Department of Biometrics, Netherlands Cancer Institute (NKI) , Amsterdam , The Netherlands., Joore MA; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre (MUMC) , Maastricht , The Netherlands.; Care and Public Health Research Institute (CAPHRI), Maastricht University , Maastricht , The Netherlands., De Ruysscher DKM; Department of Radiation Oncology (Maastro clinic), Maastricht University Medical Center, GROW Research Institute , Maastricht , The Netherlands.

المصدر: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2019 Oct; Vol. 58 (10), pp. 1528-1531. Date of Electronic Publication: 2019 Jul 01.

نوع المنشور: Letter

بيانات الدورية: Publisher: Medical Journals Sweden AB Country of Publication: England NLM ID: 8709065 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Cranial Irradiation*, Brain Neoplasms/*prevention & control , Carcinoma, Non-Small-Cell Lung/*prevention & control , Chemoradiotherapy/*methods , Lung Neoplasms/*pathology, Age Factors ; Brain Neoplasms/epidemiology ; Brain Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/epidemiology ; Carcinoma, Non-Small-Cell Lung/secondary ; Clinical Trials, Phase III as Topic ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/therapy ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors ; Sex Factors ; Time Factors ; Treatment Outcome

المؤلفون: De Ruysscher D; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Dingemans AC; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Praag J; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Belderbos J; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Tissing-Tan C; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Herder J; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Haitjema T; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Ubbels F; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Lagerwaard F; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., El Sharouni SY; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Stigt JA; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Smit E; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., van Tinteren H; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., van der Noort V; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Groen HJM; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2018 Aug 10; Vol. 36 (23), pp. 2366-2377. Date of Electronic Publication: 2018 May 22.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Brain Neoplasms/*radiotherapy , Brain Neoplasms/*secondary , Carcinoma, Non-Small-Cell Lung/*pathology , Carcinoma, Non-Small-Cell Lung/*radiotherapy , Cranial Irradiation/*methods , Lung Neoplasms/*pathology , Lung Neoplasms/*radiotherapy, Brain Neoplasms/prevention & control ; Cranial Irradiation/adverse effects ; Female ; Humans ; Male ; Neoplasm Staging ; Progression-Free Survival ; Quality of Life ; Survival Rate

المؤلفون: Slotman BJ; VU University Medical Center, Amsterdam, Netherlands. Electronic address: bj.slotman@vumc.nl., Faivre-Finn C; University of Manchester & The Christie NHS Foundation Trust, Manchester, United Kingdom., van Tinteren H; NKI, Amsterdam, Netherlands., Keijser A; IKNL, Amsterdam, Netherlands., Praag J; Erasmus MC Cancer Center, Rotterdam, Netherlands., Knegjens J; NKI-AvL, Amsterdam, Netherlands., Hatton M; Weston Park Hospital, Sheffield, United Kingdom., van Dam I; UMC Utrecht, Utrecht, Netherlands., van der Leest A; UMCG, Groningen, Netherlands., Reymen B; Maastro Clinic, Maastricht, Netherlands., Stigt J; Isala ziekenhuis, Zwolle, Netherlands., Haslett K; University of Manchester & The Christie NHS Foundation Trust, Manchester, United Kingdom., Tripathi D; Weston Park Hospital, Sheffield, United Kingdom., Smit EF; VU University Medical Center, Amsterdam, Netherlands., Senan S; VU University Medical Center, Amsterdam, Netherlands.

المصدر: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2017 Jun; Vol. 108, pp. 150-153. Date of Electronic Publication: 2017 Mar 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Radiotherapy*/adverse effects , Radiotherapy*/methods, Lung Neoplasms/*pathology , Lung Neoplasms/*radiotherapy , Small Cell Lung Carcinoma/*pathology , Small Cell Lung Carcinoma/*radiotherapy, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Clinical Trials, Phase III as Topic ; Combined Modality Therapy ; Female ; Humans ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Prognosis ; Small Cell Lung Carcinoma/mortality ; Survival Analysis ; Treatment Outcome

المؤلفون: Nuyttens JJ; Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. j.nuyttens@erasmusmc.nl, van der Voort van Zyp NC, Praag J, Aluwini S, van Klaveren RJ, Verhoef C, Pattynama PM, Hoogeman MS

المصدر: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2012 Mar; Vol. 102 (3), pp. 383-7. Date of Electronic Publication: 2012 Jan 20.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8407192 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0887 (Electronic) Linking ISSN: 01678140 NLM ISO Abbreviation: Radiother Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Lung Neoplasms/*surgery , Radiosurgery/*methods, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Radiosurgery/adverse effects ; Radiotherapy Dosage ; Treatment Outcome ; Tumor Burden

المؤلفون: Surmont V; Department of Respiratory Medicine, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. veerle.surmont@uzgent.be, Smit EF, de Jonge M, Aerts JG, Nackaerts K, Vernhout R, Gras J, Van Wijk A, Phernambucq EC, van Meerbeeck JP, Senan S, Kraaij CJ, Chouaki N, Praag J, van Klaveren RJ

المصدر: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2010 Sep; Vol. 69 (3), pp. 302-6. Date of Electronic Publication: 2010 Jan 22.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Maximum Tolerated Dose*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , Carcinoma, Small Cell/*drug therapy , Lung Neoplasms/*drug therapy, Aged ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/physiopathology ; Carcinoma, Small Cell/mortality ; Carcinoma, Small Cell/pathology ; Carcinoma, Small Cell/physiopathology ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Combined Modality Therapy ; Disease Progression ; Early Termination of Clinical Trials ; Female ; Follow-Up Studies ; Glutamates/administration & dosage ; Glutamates/adverse effects ; Guanine/administration & dosage ; Guanine/adverse effects ; Guanine/analogs & derivatives ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Lung Neoplasms/physiopathology ; Male ; Middle Aged ; Neoplasm Staging ; Pemetrexed ; Survival Analysis

المؤلفون: van der Voort van Zyp NC; Radiation Oncology Department, Daniel den Hoed-Erasmus Medical Center, Rotterdam, The Netherlands. n.vandervoortvanzyp@erasmusmc.nl, Prévost JB, Hoogeman MS, Praag J, van der Holt B, Levendag PC, van Klaveren RJ, Pattynama P, Nuyttens JJ

المصدر: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2009 Jun; Vol. 91 (3), pp. 296-300. Date of Electronic Publication: 2009 Mar 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8407192 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0887 (Electronic) Linking ISSN: 01678140 NLM ISO Abbreviation: Radiother Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung/*surgery , Lung Neoplasms/*surgery , Radiosurgery/*methods, Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/pathology ; Comorbidity ; Dose Fractionation, Radiation ; Female ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Proportional Hazards Models ; Radiation Injuries/etiology ; Radiotherapy Dosage ; Radiotherapy Planning, Computer-Assisted/methods ; Survival Rate ; Tomography, X-Ray Computed ; Treatment Outcome

المؤلفون: Prevost JB; Department of Radiation-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands., Voet P, Hoogeman M, Praag J, Levendag P, Nuyttens JJ

المصدر: Technology in cancer research & treatment [Technol Cancer Res Treat] 2008 Feb; Vol. 7 (1), pp. 27-33.

نوع المنشور: Comparative Study; Journal Article

بيانات الدورية: Publisher: SAGE Country of Publication: United States NLM ID: 101140941 Publication Model: Print Cited Medium: Print ISSN: 1533-0346 (Print) Linking ISSN: 15330338 NLM ISO Abbreviation: Technol Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Radiotherapy Planning, Computer-Assisted*, Carcinoma, Non-Small-Cell Lung/*surgery , Lung Neoplasms/*surgery , Radiosurgery/*methods, Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/radiotherapy ; Female ; Humans ; Lung Neoplasms/radiotherapy ; Male ; Middle Aged ; Radiotherapy, Conformal